The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
Abstract
OBJECTIVE: To evaluate the efficacy and safety of 500 mg bid and 1500 mg bid levetiracetam as adjunctive therapy for refractory partial seizures in a double-blind, randomized, placebo-controlled, parallel-group, multicenter trial. METHODS: The authors studied patients with uncontrolled partial seizures (minimum 12 per 12 weeks), regardless of whether they became secondarily generalized, for 38 weeks. A 12-week baseline was followed by random assignment to adjunctive therapy with placebo (n = 95), levetiracetam 1000 mg/day (n = 98), or levetiracetam 3000 mg/day (n = 101). Upward titration over 4 weeks was followed by 14 weeks of fixed dose treatment, and concluded with an 8-week medication withdrawal period or entering a follow-up study. RESULTS: Of 294 patients randomized, 268 completed the study. Partial seizure frequency during the entire evaluation period (primary efficacy variable) was lower with levetiracetam compared to placebo (p </= 0.001 for both groups). More patients responded (defined as minimum 50% reduction in partial seizure frequency) to levetiracetam than placebo, with rates of 33. 0% in the 1000 mg/day and 39.8% in the 3000 mg/day group, compared to 10.8% in the placebo group (p < 0.001). Of 199 patients receiving levetiracetam, 11 became seizure free; no patient became seizure free in the placebo group. Treatment-emergent adverse events (>/=10%), mostly mild to moderate in severity, with incidences higher than placebo were asthenia, dizziness, flu syndrome, headache, infection, rhinitis, and somnolence. CONCLUSION: Adjunctive therapy with levetiracetam was effective and well tolerated in controlling partial seizures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory
Cramer, J. A., Perrine, K., Devinsky, O., Bryant‐Comstock, L., Meador, K., & Hermann, B. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01278.x · Cited by 782
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506
Löscher, W., Hönack, D., & Rundfeldt, C. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37251-9 · Cited by 343
Löscher, W., & Hönack, D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90768-d · Cited by 281
ucb L059, a novel anti-convulsant drug: pharmacological profile in animais
Gower, A. J., Noyer, M., Verloes, R., Gobert, J., & Wülfert, E. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90855-x · Cited by 212
Gower, A. T., Hirsch, E., Boehrer, A., Noyer, M., & Marescaux, C. (1995) · Epilepsy Research · doi:10.1016/0920-1211(95)00077-1 · Cited by 198
Kasteleijn-Nolst Trenité, D. G. A., Marescaux, C., Stodieck, S., Edelbroek, P. M., & Oosting, J. (1996) · Epilepsy Research · doi:10.1016/s0920-1211(96)00031-9 · Cited by 183
Effect of Levetiracetam on Epilepsy‐Related Quality of Life
Cramer, J. A., Arrigo, C., Hammée, G. V., Gauer, L. J., Cereghino, J. J., & for the N132 Study Group (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00255.x · Cited by 136
Self-citationIn Vitro Evaluation of Potential Drug Interactions With Levetiracetam, A New Antiepileptic Agent
Nicolas, J.-M., Collart, P., Gerin, B., MATHER, G. G., Trager, W. F., Levy, R. H., & Roba, J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15285-3 · Cited by 121
Multiple Subpial Transection in Patients with Extratemporal Epilepsy
Smith, M. C. F. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb05128.x · Cited by 68
Cited by
Book Review: GABA and Glutamate in the Human Brain
Petroff, O. A. C. (2002) · The Neuroscientist · doi:10.1177/1073858402238515 · Cited by 675
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Self-citationHeck, C. N., King‐Stephens, D., Massey, A. D., Nair, D. R., Jobst, B. C., Barkley, G. L., Salanova, V., Cole, A. J., Smith, M. C., Gwinn, R. P., et al. (2014) · Epilepsia · doi:10.1111/epi.12534 · Cited by 651
Clinical Pharmacokinetics of Levetiracetam
Patsalos, P. N. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00002 · Cited by 473
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
Brodie, M. J., Perucca, E., Ryvlin, P., Ben-Menachem, E., & Meencke, H.-J. (2007) · Neurology · doi:10.1212/01.wnl.0000252941.50833.4a · Cited by 467
Metadata
- Authors
- Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I., & the United States Levetiracetam Study Group
- Venue
- Neurology
- Published
- 2000-07-25
- Volume
- 55
- Issue
- 2
- Pages
- 236-242
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2025490080
- Cited by
- 524
- References
- 11
- FWCI
- 24.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.